## **Appendix 3B**

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

ENTEK ENERGY LIMITED

ABN

43 108 403 425

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued Performance Rights

- 2 Number of <sup>+</sup>securities issued or to be issued (if known) or maximum number which may be issued
- 3 Principal terms of the <sup>+</sup>securities (e.g. if options, exercise price and expiry date; if partly paid <sup>+</sup>securities, the amount outstanding and due dates for payment; if <sup>+</sup>convertible securities, the conversion price and dates for conversion)
- a) 5,000,000 Performance Rights,
- b) 5,000,000 Performance Rights,
- c) 5,000,000 Performance Rights,
- d) 5,000,000 Performance Rights.
- a) Class A Performance Rights with terms and milestones as set out in the Notice of Meeting dated 2 July 2019,
- b) Class B Performance Rights with terms and milestones as set out in the Notice of Meeting dated 2 July 2019,
- c) Class C Performance Rights with terms and milestones as set out in the Notice of Meeting dated 2 July 2019,
- d) Class D Performance Rights with terms and milestones as set out in the Notice of Meeting dated 2 July 2019,

4		) No best on a commission internalization
4	Do the <sup>+</sup> securities rank equally in all respects from the <sup>+</sup> issue date with an	<ul> <li>a) No, but upon conversion into ordinary shares, yes.</li> </ul>
	existing +class of quoted +securities?	b) No, but upon conversion into ordinary shares, yes.
	If the additional <sup>+</sup> securities do not rank equally, please state:	<ul><li>c) No, but upon conversion into ordinary shares, yes.</li></ul>
	<ul> <li>the date from which they do</li> </ul>	d) No, but upon conversion into ordinary
	• the extent to which they participate for the next dividend, (in the case	shares, yes.
	of a trust, distribution) or interest payment	
	• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or	
	interest payment	
5	Issue price or consideration	Nil cash consideration.
5	Toble pree of consideration	
6	Purpose of the issue	Issued to Managing Director pursuant to the
0	(If issued as consideration for the	terms and milestones as set out in the Notice of
	acquisition of assets, clearly identify those assets)	Meeting dated 2 July 2019.
		N
6a	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A?	No
	If Yes, complete sections 6b - 6h in	
	relation to the + securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution	NA
00	under rule 7.1A was passed	
6c	Number of <sup>+</sup> securities issued without	Nil
	security holder approval under rule 7.1	
6d	Number of +securities issued with	NA
	security holder approval under rule 7.1A	
_		
6e	Number of <sup>+</sup> securities issued with security holder approval under rule	20,000,000 Performance Rights as approved by shareholders at the General Meeting on 1 August
	7.3, or another specific security holder approval (specify date of meeting)	2019.
		L
6f	Number of <sup>+</sup> securities issued under an exception in rule 7.2	N/A

<sup>+</sup> See chapter 19 for defined terms.

- If +securities issued under rule 7.1A, 6g was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.
- If +securities were issued under rule 6h 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- Calculate the entity's remaining issue 6i capacity under rule 7.1 and rule 7.1A complete Annexure 1 and release to ASX Market Announcements
- <sup>+</sup>Issue dates 7

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

Number and +class of all +securities 8 quoted on ASX (including the <sup>+</sup>securities in section 2 if applicable)

	Number	+Class
;	471,443,887	Ordinary fully paid shares.

N/A

N/A

73,459,340 7.1A Nil

5 August 2019

7.1

		Number	+Class
9	Number and <sup>+</sup> class of all <sup>+</sup> securities	18,285,047	Ordinary fully paid shares subject
-	not quoted on ASX (including the		to restriction agreements until 30
	<sup>+</sup> securities in section 2 if applicable)		April 2020.
			1
		10,000,000	Options Exercisable at \$0.04 on
			or before 31 March 2020.
		3,000,000	Options Exercisable at \$0.048 on
			or before 28 November 2020.
		3,000,000	Options Exercisable at \$0.072 on
			or before 28 November 2020.
		3,000,000	Options Exercisable at \$0.096 on
			or before 28 November 2020.
		1 000 000	
		1,000,000	Options Exercisable at \$0.048 on
			or before 4 December 2021.
		1,000,000	Options Exercisable at \$0.072 on
		1,000,000	or before 4 December 2021.
			of before 4 December 2021.
		1,000,000	Options Exercisable at \$0.096 on
		1,000,000	or before 4 December 2021.
			of Schole + December 2021.
		4,000,000	Options Exercisable at \$0.048 on
			or before 4 December 2021,
			vesting immediately.
			0 ,
		20,000,000	Class A, B, C and D Performance
		-	Rights with terms and milestones
			as set out in the Notice of
			Meeting dated 2 July 2019.
			· · · · · · · · · · · · · · · · · · ·

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

The Company has not formulated a dividend policy at this time.

## Part 2 - Pro rata issue

11 Is security holder approval N/A required?

N/A

- 12 Is the issue renounceable or non- N/A renounceable?
- 13 Ratio in which the <sup>+</sup>securities N will be offered

s N/A

<sup>+</sup> See chapter 19 for defined terms.

14       *Class of *securities to which the offer relates       N/A         15       *Record date to determine entitlements       N/A         16       Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?       N/A         17       Policy for deciding entitlements in relation to fractions       N/A         18       Names of countries in which the entity has security holders who will not be sent new offer documents       N/A         19       Closing date for receipt of acceptances or renunciations       N/A         20       Names of any underwriting fee or commission       N/A         21       Amount of any underwriting fee or commission       N/A         22       Names of any brokers to the issue       N/A         23       Fee or commission payable to the broker to the issue       N/A         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders       N/A         24       Amount of any commission       N/A         25       If the issue is contingent on security holders' approval, the date of the meeting       N/A         26       Date entitlement and acceptance form and offer documents will be sent to option holders to participate on exercise, the date on which notices will be sent to option holders       N/A			
entitlements         16       Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?         17       Policy for deciding entitlements         18       Names of countries in which the entity has security holders who will not be sent new offer documents         18       Names of countries in which the entity has security holders who will not be sent new offer documents         19       Closing date for receipt of acceptances or renunciations         20       Names of any underwriters         21       Amount of any underwriting fee or commission         22       Names of any brokers to the issue         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee acceptances or renunciations on behalf of security holders         25       If the issue is contingent on security holders' approval, the date of the meeting         26       Date entitlement and acceptance for mad offer documents will be sent to persons entitled         27       If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option	14		N/A
registers (or subregisters) be aggregated for calculating entitlements? Policy for deciding entitlements in relation to fractions NA entitlements? Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be data with. Cross reference: rule 7.7. Closing date for receipt of acceptances or renunciations N/A Cross reference: rule 7.7. Closing date for receipt of acceptances or renunciations N/A Amount of any underwriters N/A Amount of any underwriting fee or commission Amount of any brokers to the issue Amount of any horkers to the issue Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders Fee or commission payable to the broker such lodge acceptances or renunciations on behalf of security holders Closs entitlement and acceptance form and offer documents will be sent to persons entitled The entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option	15		N/A
in relation to fractions         18       Names of countries in which the entity has security holders who will not be sent new offer documents         Note: Security holders must be told how their entitlements are to be dealt with.         Cross reference: rule 7.7.         19       Closing date for receipt of acceptances or renunciations         20       Names of any underwriters         21       Amount of any underwriting fee or commission         22       Names of any brokers to the issue         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders         25       If the issue is contingent on security holders' approval, the date of the meeting         26       Date entitlement and acceptance form and offer documents will be sent to persons entitled         27       If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option	16	registers (or subregisters) be aggregated for calculating	N/A
entity has security holders who will not be sent new offer documents         Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.         19       Closing date for receipt of acceptances or renunciations         20       Names of any underwriters         21       Amount of any underwriting fee or commission         22       Names of any brokers to the issue         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders         25       If the issue is contingent on security holders' approval, the date of the meeting         26       Date entitlement and acceptance form and offer documents will be sent to persons entitled         27       If the entity has issued options, and the terms entitle option holders to participate on withe sent to option	17		N/A
Cross reference: rule 7.7.         19       Closing date for receipt of acceptances or renunciations         20       Names of any underwriters         21       Amount of any underwriting fee or commission         22       Names of any brokers to the issue         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders         25       If the issue is contingent on security holders' approval, the date of the meeting         26       Date entitlement and acceptance form and offer documents will be sent to persons entitled         27       If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option	18	entity has security holders who will not be sent new offer documents Note: Security holders must be told how their	N/A
acceptances or renunciations         20       Names of any underwriters         21       Amount of any underwriting fee or commission         22       Names of any brokers to the issue         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders         25       If the issue is contingent on security holders' approval, the date of the meeting         26       Date entitlement and acceptance form and offer documents will be sent to persons entitled         27       If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option			
21       Amount of any underwriting fee or commission       N/A         22       Names of any brokers to the issue       N/A         23       Fee or commission payable to the broker to the issue       N/A         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders       N/A         25       If the issue is contingent on security holders' approval, the date of the meeting       N/A         26       Date entitlement and acceptance form and offer documents will be sent to persons entitled       N/A         27       If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option       N/A	19		N/A
or commission         22       Names of any brokers to the issue         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders         25       If the issue is contingent on security holders' approval, the date of the meeting         26       Date entitlement and acceptance form and offer documents will be sent to persons entitled         27       If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option	20	Names of any underwriters	N/A
<ul> <li>issue</li> <li>23 Fee or commission payable to the broker to the issue</li> <li>24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders</li> <li>25 If the issue is contingent on security holders' approval, the date of the meeting</li> <li>26 Date entitlement and acceptance form and offer documents will be sent to persons entitled</li> <li>27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option</li> </ul>	21		N/A
the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders         25       If the issue is contingent on security holders' approval, the date of the meeting         26       Date entitlement and acceptance form and offer documents will be sent to persons entitled         27       If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option	22		N/A
payable to brokers who lodge         acceptances or renunciations on         behalf of security holders         25       If the issue is contingent on         security holders' approval, the       N/A         26       Date entitlement and acceptance         form and offer documents will be       N/A         27       If the entity has issued options, and the terms entitle option         holders to participate on       exercise, the date on which         notices will be sent to option       N/A	23		N/A
<ul> <li>security holders' approval, the date of the meeting</li> <li>26 Date entitlement and acceptance form and offer documents will be sent to persons entitled</li> <li>27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option</li> </ul>	24	payable to brokers who lodge acceptances or renunciations on	N/A
form and offer documents will be sent to persons entitled 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option	25	security holders' approval, the	N/A
and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option	26	form and offer documents will be	N/A
	27	and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option	N/A

28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	<sup>+</sup> Issue date	N/A

### Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of <sup>+</sup>securities (*tick one*)
- (a) \*Securities described in Part 1
  - All other <sup>+</sup>securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

#### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35

(b)

If the <sup>+</sup>securities are <sup>+</sup>equity securities, the names of the 20 largest holders of the additional <sup>+</sup>securities, and the number and percentage of additional <sup>+</sup>securities held by those holders

<sup>+</sup> See chapter 19 for defined terms.

37

If the \*securities are \*equity securities, a distribution schedule of the additional \*securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over

A copy of any trust deed for the additional \*securities

#### **Quotation agreement**

- <sup>1</sup> <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those *\*securities* should not be granted *\*quotation*.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	Arron Canicais ( <del>Director</del> /Company Secretary)	Date: 5 August 2019
Print name:	ARRON CANICAIS== == == ==	=

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

## Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
<b>Insert</b> number of fully paid <sup>+</sup> ordinary securities on issue 12 months before the <sup>+</sup> issue date or date of agreement to issue,	304,728,934	
<ul> <li>Add the following:</li> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> </ul>	Nil	
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval	185,000,000 on conversion of CPS, the subject of this Appendix 3B	
<ul> <li>Number of partly paid <sup>+</sup>ordinary securities that became fully paid in that 12 month period</li> </ul>	Nil	
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
Subtract the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	Nil	
"A"	489,728,934	

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"В"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	73,459,340	
Step 3: Calculate "C", the amount of p rule 7.1 that has already been used	lacement capacity under	
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period not counting those issued:	Nil	
<ul><li>Under an exception in rule 7.2</li><li>Under rule 7.1 A</li></ul>		
<ul> <li>With security holder approval under rule</li> <li>7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	Nil	
Step 4: Subtract "C" from ["A" x "B"] to placement capacity under rule 7.1	calculate remaining	
"A" x 0.15	73,459,340	
Note: number must be same as shown in Step 2		
Subtract "C" Note: number must be same as shown in Step 3	Nil	
<b>Total</b> ["A" x 0.15] – "C"	73,459,340	
	[Note: this is the remaining placement capacity under rule 7.1]	

<sup>+</sup> See chapter 19 for defined terms.

## Part 2

Rule 7.1A – Additional placem	Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base fig capacity is calculated	Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
<b>"A"</b> Note: number must be same as shown in Step 1 of Part 1	N/A – the Company has not obtained shareholder approval under ASX Listing Rule 7.1A in respect of additional placement capacity.		
Step 2: Calculate 10% of "A"			
"D"	0.10 Note: this value cannot be changed		
Multiply "A" by 0.10			
Step 3: Calculate "E", the amount 7.1A that has already been used	of placement capacity under rule		
<ul> <li>Insert number of tequity securities issued or agreed to be issued in that 12 month period under rule 7.1A</li> <li>Notes: <ul> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> <li>*E"</li> </ul>	"] to calculate remaining		
placement capacity under rule 7. "A" x 0.10			
Note: number must be same as shown in Step 2			

<sup>+</sup> See chapter 19 for defined terms.

Subtract "E"	
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" × 0.10] – "E"	
	Note: this is the remaining placement capacity under rule 7.1A

<sup>+</sup> See chapter 19 for defined terms.